Загрузка...
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%–30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment re...
Сохранить в:
| Опубликовано в: : | Acta Biochim Biophys Sin (Shanghai) |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4689161/ https://ncbi.nlm.nih.gov/pubmed/26578706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/abbs/gmv118 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|